Michael Martin Breen - Feb 16, 2021 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Role: Director
Signature: /s/ Michael Martin Bree
Stock symbol: GTBP
Transactions as of: Feb 16, 2021
Transactions value $: $170,347
Form type: 4
Date filed: 11/12/2021, 11:01 AM
Previous filing: Nov 12, 2021
Next filing: Jul 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GTBP	Common Stock	Award	$0	+278K		$0.00	278K	Feb 16, 2021	Direct	F1
transaction	GTBP	Common Stock	Conversion of derivative security	$137K	+40.2K	+14.47%	$3.40^*	318K	Feb 25, 2021	Direct
transaction	GTBP	Common Stock	Conversion of derivative security	$33.5K	+9.86K	+3.1%	$3.40^*	328K	Feb 25, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GTBP	Option to purchase Common Stock	Award	$0	+50K		$0.00	50K	Feb 16, 2021	Common Stock	50K	$6.33	Direct	F2
transaction	GTBP	10% Senior Convertible Debenture	Conversion of derivative security	$0	-100K	-100%	$0.00^*	0	Feb 25, 2021	Common Stock	40.2K	$3.40	Direct	F3
transaction	GTBP	10% Senior Convertible Debenture	Conversion of derivative security	$0	-30K	-100%	$0.00^*	0	Feb 25, 2021	Common Stock	9.86K	$3.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023.
F2	1/3rd of the shares vest on February 16, 2021, 2022 and 2023.
F3	While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding until converted.